Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBU OTCMKTS:MRMD NASDAQ:PRQR NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$2.38-4.4%$1.98$0.66▼$3.00$221.63M2.591.29 million shs766,408 shsMRMDMariMed$0.17$0.14$0.07▼$0.23$64.78M2.98769,227 shs908,492 shsPRQRProQR Therapeutics$2.29-5.0%$2.19$1.07▼$4.62$240.94M0.23419,013 shs350,766 shsRENBLunai Bioworks$1.54+21.7%$2.04$1.13▼$21.00$250.24M0.543.75 million shs880,400 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences0.00%+9.69%+38.33%+46.47%+31.05%MRMDMariMed0.00%+6.45%+20.09%+67.68%+6.45%PRQRProQR Therapeutics0.00%-1.63%+10.05%-2.82%+30.27%RENBLunai Bioworks0.00%0.00%-22.45%-44.96%-69.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$2.38-4.4%$1.98$0.66▼$3.00$221.63M2.591.29 million shs766,408 shsMRMDMariMed$0.17$0.14$0.07▼$0.23$64.78M2.98769,227 shs908,492 shsPRQRProQR Therapeutics$2.29-5.0%$2.19$1.07▼$4.62$240.94M0.23419,013 shs350,766 shsRENBLunai Bioworks$1.54+21.7%$2.04$1.13▼$21.00$250.24M0.543.75 million shs880,400 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences0.00%+9.69%+38.33%+46.47%+31.05%MRMDMariMed0.00%+6.45%+20.09%+67.68%+6.45%PRQRProQR Therapeutics0.00%-1.63%+10.05%-2.82%+30.27%RENBLunai Bioworks0.00%0.00%-22.45%-44.96%-69.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 2.50Moderate Buy$6.67176.05% UpsideMRMDMariMed 4.00Strong BuyN/AN/APRQRProQR Therapeutics 2.89Moderate Buy$8.00241.15% UpsideRENBLunai Bioworks 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, RENB, CRBU, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRQRProQR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRQRProQR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RENBLunai BioworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/13/2025MRMDMariMedZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/8/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.99M22.51N/AN/A$2.79 per share0.87MRMDMariMed$157.96M0.39$0.02 per share7.65$0.16 per share0.98PRQRProQR Therapeutics$16.49M14.97N/AN/A$0.91 per share2.58RENBLunai BioworksN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)MRMDMariMed-$12.16M-$0.03N/A∞N/A-10.14%-10.52%-3.10%11/5/2025 (Estimated)PRQRProQR Therapeutics-$30.04M-$0.46N/AN/AN/A-238.52%-61.25%-28.13%11/6/2025 (Estimated)RENBLunai Bioworks-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%N/ALatest MRMD, RENB, CRBU, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PRQRProQR Therapeutics-$0.10N/AN/AN/A$7.05 millionN/A11/5/2025Q3 2025CRBUCaribou Biosciences-$0.36N/AN/AN/AN/AN/A11/5/2025Q3 2025MRMDMariMed-$0.01N/AN/AN/A$42.15 millionN/A8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million8/7/2025Q2 2025PRQRProQR Therapeutics-$0.08-$0.14-$0.06-$0.14$5.01 million$4.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ARENBLunai BioworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A6.666.66MRMDMariMed1.251.120.36PRQRProQR TherapeuticsN/A3.763.76RENBLunai BioworksN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%MRMDMariMed0.18%PRQRProQR Therapeutics32.65%RENBLunai Bioworks71.41%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%MRMDMariMed18.99%PRQRProQR Therapeutics8.40%RENBLunai Bioworks0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.12 million84.28 millionOptionableMRMDMariMed260392.60 million318.04 millionNot OptionablePRQRProQR Therapeutics180105.21 million96.38 millionOptionableRENBLunai Bioworks20162.39 million171.26 millionOptionableMRMD, RENB, CRBU, and PRQR HeadlinesRecent News About These CompaniesLunai Bioworks unveils new corporate identitySeptember 30, 2025 | msn.comLunai Bioworks advances biomarker discovery preclinical program in Parkinson’sSeptember 25, 2025 | msn.comLunai Bioworks Inc.: Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitSeptember 25, 2025 | finanznachrichten.deLunai Bioworks Inc.: Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma PartnershipsSeptember 25, 2025 | finanznachrichten.deLunai Bioworks to implement 10:1 reverse stock splitSeptember 25, 2025 | msn.comRenovaro Biosciences Announces Reverse Stock SplitSeptember 25, 2025 | msn.comLunai Bioworks stock plunges after announcing 10:1 reverse splitSeptember 25, 2025 | za.investing.comLunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma PartnershipsSeptember 25, 2025 | accessnewswire.comALunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitSeptember 24, 2025 | accessnewswire.comALunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder TherapeuticsSeptember 11, 2025 | accessnewswire.comARenovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesSeptember 9, 2025 | finanznachrichten.deLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug DiscoverySeptember 9, 2025 | accessnewswire.comALunai Bioworks Strengthens European Strategy Through RestructuringSeptember 8, 2025 | accessnewswire.comARenovaro BioSciences retains American Defense InternationalSeptember 4, 2025 | msn.comLunai Bioworks Inc. Retains American Defense InternationalSeptember 4, 2025 | accessnewswire.comARenovaro BioSciences to change corporate name to ‘Lunai Bioworks’August 28, 2025 | msn.comRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsAugust 27, 2025 | accessnewswire.comARenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksAugust 8, 2025 | accessnewswire.comARenovaro Biosciences Granted Nasdaq Compliance ExtensionAugust 6, 2025 | tipranks.comAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksJuly 30, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRMD, RENB, CRBU, and PRQR Company DescriptionsCaribou Biosciences NASDAQ:CRBU$2.38 -0.11 (-4.42%) Closing price 04:00 PM EasternExtended Trading$2.39 +0.01 (+0.46%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.MariMed OTCMKTS:MRMD$0.17 0.00 (0.00%) As of 03:59 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.ProQR Therapeutics NASDAQ:PRQR$2.29 -0.12 (-4.98%) Closing price 04:00 PM EasternExtended Trading$2.31 +0.02 (+0.66%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Lunai Bioworks NASDAQ:RENB$1.54 +0.28 (+21.72%) Closing price 09/30/2025Extended Trading$1.54 0.00 (0.00%) As of 09/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
